Rilmenidin

Rilmenidin
(IUPAC) ime
	N-(diciklopropilmetil)-4,5-dihidro-1,3-oksazol-2-amin
Klinički podaci
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	54187-04-1
ATC kod	C02AC06
PubChem	68712
ChemSpider	61963
UNII	P67IM25ID8
ChEMBL	CHEMBL289480
Hemijski podaci
Formula	C10H16N2O
Mol. masa	180,247 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12) ; Key: CQXADFVORZEARL-UHFFFAOYSA-N
Farmakokinetički podaci
Vezivanje za proteine plazme	7%
Metabolizam	Minimalan
Poluvreme eliminacije	8 sata
Izlučivanje	Renalno, nepromenjen
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	Oralno

Rilmenidin je lek koji se koristi za treatiranje hipertenzije.^[5] On je u prodaji pod imenima Hyperium i Tenaxum.

Tableta

Svaka tableta sadrži 1,544 mg rilmenidin dihidrogen fosfata, količinu ekvuivalentnu sa 1,000 mg slobodne baze rilmenidina.

Način dejstva

Rilmenidin je oksazolinsko jedinjenje sa antihipertenzivnim svojstvima. On deluje na medularne i periferno vazomotorne strukture. Rilmenidin ima veću selektivnost za imidazolinske receptore nego za cerebralne alfa2-adrenergičke receptore, po čemu se razlikuje od referentnih alfa-2 agonista.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Remková A, Kratochvíl'ová H (August 2002). „Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension”. J Hum Hypertens 16 (8): 549–55. DOI:10.1038/sj.jhh.1001427. PMID 12149660.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[pmid12149660-5] Remková A, Kratochvíl'ová H (August 2002). „Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension”. J Hum Hypertens 16 (8): 549–55. DOI:10.1038/sj.jhh.1001427. PMID 12149660.

[1]

[2]

[3]

[4]

[5]